OneSource Specialty Pharma Shares Sink 5% as Q4 Net Profit Plummets 95%

Synopsis: OneSource Specialty Pharma shares faced a brutal sell-off today, Wednesday, May 13, 2026, after the company reported a massive 95.33% decline in Q4 net profit. Despite a sequential recovery driven by GLP-1 (Semaglutide) launches, the year-on-year collapse in margins and a full-year net loss have left investors wary.

In a day of extreme volatility for the pharmaceutical sector, OneSource Specialty Pharma Limited (OSSPL) submitted its audited financial results for the quarter and year ended March 31, 2026, to the NSE and BSE. The numbers painted a stark picture of year-on-year (YoY) contraction: consolidated net profit for Q4 FY26 plummeted to Rs. 4.60 crore, a far cry from the Rs. 98.50 crore reported in the same period last year.

The company’s operational efficiency took a significant hit, with EBITDA margins halving to 21.5% from 42.7% YoY. For the full fiscal year 2026, the company swung to a consolidated net loss of Rs. 73.80 crore, compared to a profit of Rs. 179.7 crore in FY25. This downturn was exacerbated by a sharp spike in finance costs, which jumped to Rs. 22.4 crore for the quarter, and a marginal decline in annual revenue to Rs. 1,421.6 crore.

However, the management highlighted a “tale of two quarters,” noting that Q4 revenue surged 47% sequentially (QoQ). This recovery was fueled by the successful “Day-1” commercial launch of generic Semaglutide (GLP-1) in India and regulatory approvals in Canada.

In a major strategic shift, OneSource announced it has paused the proposed acquisition of specialty injectable assets from Steriscience, despite receiving CCI approval. Management stated they intend to re-engage with the merger only after delivering on their FY28 organic revenue guidance of $400 million.

The market response was swift and surgical. Shares of OneSource Specialty Pharma dropped as much as 5.4%following the earnings release, hitting an intraday low of Rs. 1,731 on the NSE. The fall effectively erased all gains made by the stock over the previous six months.

By mid-afternoon, the stock was trading at Rs. 1,751.80, down roughly 4.3%. With a market capitalization now hovering around Rs. 20,490 crore, the company remains a mid-cap favorite, though the high debtor days (177 days) and pledged promoter holdings (38.4%) continue to be points of contention for conservative analysts.

Despite the sharp decline in OneSource Specialty Pharma Limited shares, the broader sector presented a mixed picture. Its parent company, Strides Pharma Science Limited , was trading around Rs. 1,171.40, up nearly 1.70% during mid-morning trade, indicating that the weakness remained largely stock-specific. 

Company Overview

OneSource Specialty Pharma Ltd (a subsidiary of Strides Pharma) is a specialized Contract Development and Manufacturing Organisation (CDMO). The company focuses on the development and commercialization of complex biologics and injectables. With a strong presence in the high-growth GLP-1 market and a 100% GMP inspection success rate, OneSource serves global biopharma clients through its integrated value chain, from pre-clinical phases to large-scale commercial supply.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor.

The post OneSource Specialty Pharma Shares Sink 5% as Q4 Net Profit Plummets 95% appeared first on Trade Brains.